TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01144533

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: isotonic saline injection into the glenohumeral joint
Description: * Total volume of injection drugs: 8ml~* isotonic saline 4ml + telebrix(contrast media) 4ml~* The number of injections : only once during the study period~* Injection site : glenohumeral joint~* Material : 22-gauze spinal needle~* Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: steroid injection into the glenohumeral joint
Description: * Total volume of injection drugs: 8ml~* triamcinolone(40mg)1ml + isotonic saline 3ml + telebrix(contrast media)4ml~* The number of injections : only once during the study period~* Injection Site : glenohumeral joint~* Material : 22-gauze spinal needle~* Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sodium hyaluronate injection into the glenohumeral joint
Description: * Total volume of injection drugs: 8ml~* sodium hyaluronate 2ml + isotonic saline 2ml + telebrix(contrast media)4ml~* The number of injections : only once during the study period~* Injection Site : glenohumeral joint~* Material : 22-gauze spinal needle~* Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: steroid and hyaluronate injection into the glenohumeral joint
Description: * Total volume of injection drugs: 8ml~* triamcinolone(40mg)1ml + sodium hyaluronate 2ml + isotonic saline 1ml + telebrix(contrast media)4ml~* The number of injections : only once during the study period~* Injection Site : glenohumeral joint~* Material : 22-gauze spinal needle~* Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection.
Study: NCT03391700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium(deep)
Description: In the group with deep relaxation during surgery, rocuronium is given by continuous infusion (0.6 mg/kg/h).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium(moderate)
Description: In the group with deep relaxation during surgery, rocuronium is given by bolus dose(0.15mg/kg) induced a train of four count of 1-2.
Study: NCT03129009

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Total intravenous anesthesia group
Description: Total intravenous anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with propofol,cisatracurium and remifentanil target controlled infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balanced anesthesia group
Description: Balanced anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with cisatracurium and remifentanil target controlled infusion and sevoflurane inhalation
Study: NCT01420198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Increased physical activity and improved food habits
Study: NCT01633359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive statin
Description: the Intensive Atorvastatin protocol indicates that once 80mg Atorvastatin will be administrated before CAG, and then will be followed with 20mg Atorvastatin daily during the entire study period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Routine statin
Description: the Routine Atorvastatin protocol indicates that 20mg Atorvastatin daily during the entire study period.
Study: NCT05281588

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro-osteoperforations
Description: All micro-osteoperforations were performed only one time in the experimental group on the same day of the installation of the upper incisors' retraction mechanics. Perforations were performed with an individualized surgical guide and a 1.6 mm diameter stainless steel surgical drill perpendicular to the alveolar bone, 3 mm deep on the buccal surface, and 5 mm, on the palate. The depth of the perforations was controlled and standardized by a cursor developed and patented by the research group. Two micro-osteoperforations were aligned vertically distally from each upper incisor. Due to the proximity of the roots in the cervical third, only the most apical perforation was performed between the two central incisors. The first perforation was performed 6 mm away from the gingival margin, and the second, 5 mm from the first, in the vertical direction.
Study: NCT03028961

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stanford Letter
Description: Receive and complete the Stanford Letter

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Undergo semi-structured, research staff-led interview

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Undergo semi-structured, research staff-led interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CA Advance Health Care Directive Form
Description: Receive and complete the CA Advance Health Care Directive Form
Study: NCT02869230

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ROLL
Description: The ROLL technique (radioguided occult lesion localization) is characterized by the injection of a radiotracer in the center of the lesion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wire-guided lesion localization
Description: wire-guided lesion localization, including better lesion centricity in relation to margins,decreased marking time, reduced surgery time, and better aesthetic outcomes
Study: NCT02089425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-103-IP

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT01577875

Intervention type: DEVICE
Group type: OTHER
Intervention: NBI with magnification
Description: After randomization of the subjects into two groups(1) NBI with magnification, 2) without magnification), one experienced endoscopist records its site, size, shape, and predicted histologic diagnosis on the every polyp observed and endoscopically resected. Two groups will be compared with each other.
Study: NCT03841370

Intervention type: PROCEDURE
Intervention: endodontic treatment
Description: Color measurements of endodontically treated teeth (incisors, canines or premolar) will be collected regardless of technique, treatment time and sealer used.
Study: NCT05684185

Intervention type: BIOLOGICAL
Intervention: Intramuscular (IM) rabies post-exposure prophylaxis
Description: one-site, 0.5 mL at Day 0, D3, D7 and D14

Intervention type: BIOLOGICAL
Intervention: Intramuscular (IM) rabies post-exposure prophylaxis
Description: one-site, 0.5 mL at Day 0, D3, D7 and D14

Intervention type: BIOLOGICAL
Intervention: Intradermal (ID) rabies post-exposure prophylaxis
Description: two-site, 0.1 mL at Day 0, D3 and D7

Intervention type: BIOLOGICAL
Intervention: Intradermal (ID) rabies post-exposure prophylaxis
Description: two-site, 0.1 mL at Day 0, D3 and D7
Study: NCT02625714

Intervention type: DRUG
Group type: OTHER
Intervention: Renexin®
Description: Cilostazol 100mg/ginko biloba leaf extract 80mg, Immediate release, bid

Intervention type: DRUG
Group type: OTHER
Intervention: Renexin®
Description: Cilostazol 100mg/ginko biloba leaf extract 80mg, Immediate release, bid

Intervention type: DRUG
Group type: OTHER
Intervention: SID142
Description: Cilostazol 200mg/ginko biloba leaf extract 160mg, Controlled release, qd

Intervention type: DRUG
Group type: OTHER
Intervention: SID142
Description: Cilostazol 200mg/ginko biloba leaf extract 160mg, Controlled release, qd
Study: NCT03249103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NYX-2925
Description: NYX-2925 is a novel small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Matching placebo capsules.
Study: NCT03784807

Intervention type: DIAGNOSTIC_TEST
Intervention: synovial calprotectin, confocal laser microscopy
Description: Calprotectin will be determined in synovial fluid of patients with septic and aseptic failure of their prosthesis. CLSM will be used to detect presence of microorganisms in synovial fluid. Susceptibility to antimicrobials of bacterial strains isolated from patients with prosthetic joint infections will be assessed using planktonic cells and biofilm associated bacteria

Intervention type: DIAGNOSTIC_TEST
Intervention: synovial calprotectin, confocal laser microscopy
Description: Calprotectin will be determined in synovial fluid of patients with septic and aseptic failure of their prosthesis. CLSM will be used to detect presence of microorganisms in synovial fluid. Susceptibility to antimicrobials of bacterial strains isolated from patients with prosthetic joint infections will be assessed using planktonic cells and biofilm associated bacteria
Study: NCT03465930

Intervention type: PROCEDURE
Intervention: Supermicrosurgical lymphatico-venous anastomoses
Description: Supermicrosurgical lymphatico-venous anastomoses (sLVA) require an accurate visualization of the lymphatic vessels that are still functional. Lymphatic vessels are visualized with lymphography using a fluorescent dye, indocyanine green. Adjacent superficial veins mapping is obtained with Accuvein device.
Study: NCT03286283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: J-Plasma
Description: Dermal resurfacing procedure with J-Plasma.
Study: NCT03615066

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet(s) administered orally every 7 days for 24 doses in fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet(s) administered orally every 7 days for 24 doses in fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selgantolimod
Description: Tablet(s) administered orally every 7 days for 24 doses in fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selgantolimod
Description: Tablet(s) administered orally every 7 days for 24 doses in fasted state

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAF
Description: Tablet(s) administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: Tablet(s) administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: Tablet(s) administered orally once daily with food
Study: NCT02359227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenderitide
Description: Cenderitide is a dual receptor natriuretic peptide.
Study: NCT01577472

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Dose Clomiphencitrat
Description: 100mg of clomiphencitrate(Serophene®) are added to a high dose of HMG (450 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Clomiphencitrat
Description: 100mg of clomiphencitrate(Serophene®) are added to a low dose of HMG (150 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: High Dose Placebo
Description: Placebo is added to a high dose of HMG (450 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low dose Placebo
Description: Placebo is added to a low dose of HMG (150 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
Study: NCT01973504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP4OX
Description: 4.3 g/dL pegylated hemoglobin in balanced lactate-electrolyte solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP4OX
Description: 4.3 g/dL pegylated hemoglobin in balanced lactate-electrolyte solution

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Crystalloid solution IV infusion drip to keep vein open
Study: NCT02104947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarucizumab
Description: idarucizumab
Study: NCT04130698

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distress Tolerance
Description: The group-level intervention is comprised of one 2-hour weekly group sessions with overweight smokers to learn skills and strategies consistent with distress tolerance intervention to quit smoking and lose weight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: transdermal nicotine patch
Description: Participants will use the patch for 8 weeks as outlined by the recommended usage for steps 1-3 going from 21mg for 4 weeks, 14mg for 1 week, and 7mg for 1 week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: transdermal nicotine patch
Description: Participants will use the patch for 8 weeks as outlined by the recommended usage for steps 1-3 going from 21mg for 4 weeks, 14mg for 1 week, and 7mg for 1 week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Health Control
Description: The group-level intervention is comprised of one 2-hour weekly group sessions with overweight smokers to learn skills and strategies consistent with psychoeducation intervention to quit smoking and lose weight.
Study: NCT02954666

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radio-frequency ablation
Description: Patients will undergo a tailored 'radio-frequency ablation' of the ARGP with the Smart Touch™ catheter or with the nMARQ™ catheter. Radiofrequency applications will be interrupted if no significant P-P interval shortening is observed after 30 seconds or if P-P interval is ≤ 550 ms during ablation.~The ablation procedure is considered complete when one of the following conditions is fulfilled:~P-P interval \< 70% baseline procedural P-P interval after 5minute of waiting time; P-P interval \< 600 ms after 5 minute of waiting time; 5 radiofrequency applications \> 30 seconds have been delivered with the nMARQ™ catheter or 10 applications with the Smart Touch catheter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radio-frequency ablation
Description: Patients will undergo a tailored 'radio-frequency ablation' of the ARGP with the Smart Touch™ catheter or with the nMARQ™ catheter. Radiofrequency applications will be interrupted if no significant P-P interval shortening is observed after 30 seconds or if P-P interval is ≤ 550 ms during ablation.~The ablation procedure is considered complete when one of the following conditions is fulfilled:~P-P interval \< 70% baseline procedural P-P interval after 5minute of waiting time; P-P interval \< 600 ms after 5 minute of waiting time; 5 radiofrequency applications \> 30 seconds have been delivered with the nMARQ™ catheter or 10 applications with the Smart Touch catheter.
Study: NCT02448290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel plus selumetinib
Description: Selumetinib will be administered orally 75mg twice a day continuously. Docetaxel will be administered as an IV infusion over 1 hour at 60 mg/m2 every 3 week of a 21 days schedule.
Study: NCT02708485

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: A 3-month walking program (3 times a week for 12 weeks) on treadmill supervised by a physiotherapist. Duration of the exercise is progressively increased from 15 min to 45 min over a 6-week period and the intensity of the exercise is moderate (a 12-13 score on Borg scale).
Study: NCT00738218

Intervention type: OTHER
Group type: OTHER
Intervention: Multidetector Computed Tomography - 64 detectors
Description: Multidetector computed tomography angiography
Study: NCT01707082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06282999
Description: Tablet, 10 mg, every 8 hours, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet, 0 mg, every 8 hours, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06282999
Description: Tablet, 30 mg, every 8 hours, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet, 0 mg, every 8 hours, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06282999
Description: Tablet, 100 mg, every 8 hours, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet, 0 mg, every 8 hours, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06282999
Description: Tablet, 250 mg, every 8 hours, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet, 0 mg, every 8 hours, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06282999
Description: Tablet, 350 mg every 8 hours or 500 mg every 12 hours, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet, 0 mg, every 8 or 12 hours, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: Tablet, 7.5 mg, single dose on Period 1 Day 1 and Period 2 Day 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06282999
Description: Tablet, dose to be determined (determined in Part A), every 8 or 12 hours, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: Tablet, 7.5 mg, single dose on Period 1 Day 1 and Period 2 Day 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06282999
Description: Tablet, dose to be determined (determined in Part A), every 8 or 12 hours, 14 days
Study: NCT04212689

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Game Based Virtual Reality Exercises
Description: A game-based virtual reality device named USE-IT will be added to the rehabilitation program. USE-IT is a technological rehabilitation system designed by the Department of Physiotherapy and Rehabilitation at Hacettepe University. It is a smart gaming device which has been used in patients who suffer from movement loss in their upper extremities due to various neurological and orthopedic reasons.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy and Rehabilitation
Description: The conventional physiotherapy and rehabilitation program includes stretching exercises, neurodevelopmental approaches, static positioning, strengthening exercises, Transcutaneous Electrical Nerve Stimulation (TENS), hydrotherapy, cryotherapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy and Rehabilitation
Description: The conventional physiotherapy and rehabilitation program includes stretching exercises, neurodevelopmental approaches, static positioning, strengthening exercises, Transcutaneous Electrical Nerve Stimulation (TENS), hydrotherapy, cryotherapy.
Study: NCT01218399

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Symbicort
Study: NCT00667667

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vertical vibration device (Vibrafit whole body vibration platform)
Description: 3 sessions/week 15 min each, leg exercises performed on whole body vibration platforms with vertical device
Study: NCT04525950

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Navio
Description: New generation computer navigation with haptics and robotics

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: Total knee arthroplasty using conventional instruments
Study: NCT00679185

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: expressive writing
Description: four non-emotional writing assignments

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: expressive writing
Description: four non-emotional writing assignments
Study: NCT04149951

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vestal Device
Description: Vestibular nerve stimulator

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo device
Description: Sham nerve stimulator
Study: NCT04639284

Intervention type: DRUG
Intervention: Anti-angiogenic agents plus anti-PD-1/PD-L1 antibodies
Description: Combination therapies with an anti-angiogenic agent (tyrosine kinase inhibitor or VEGF/VEGFR antibody) and an anti-PD-1/PD-L1 antibody.
Study: NCT00098605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00070642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPG 7909 Injection
Description: CPG 7909 Injection administered subcutaneously at a dose of 40 mg weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine
Description: dacarbazine 850mg/m2 in three-week cycles until disease progression
Study: NCT00098605

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT02094417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG531
Description: Subcutaneous, weekly injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG531
Description: Subcutaneous, weekly injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG531
Description: Subcutaneous, weekly injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG531
Description: Subcutaneous, weekly injection
Study: NCT00444587

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Second line chemotherapy
Description: As prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second line chemotherapy
Description: As prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab [Herceptin]
Description: 6mg/kg iv every 3 weeks